Agios Pharmaceuticals Inc. (AGIO) reported Friday morning that its Phase 1 study of AG-221 in advanced hematologic malignancies had an overall response rate of 40 percent and a complete remission rate of 16 percent.
The company also reported that its Phase 1 study of AG-120 in advanced hematologic malignancies had an overall response rate of 31 percent and a complete remission rate of 15 percent.
Agios Pharmaceuticals gapped open sharply lower Friday and declined until mid-morning. The stock recovered some ground during the first half of the afternoon, but finished down by 12.46 at $110.13 on strong volume. Agios Pharmaceuticals dropped to a 1-month low.
For comments and feedback contact: editorial@rttnews.com
Business News